万泰生物拟使用不超过12亿元闲置募集资金进行现金管理

Core Viewpoint - Wantai Biological Pharmacy (万泰生物) announced plans to invest up to 1.2 billion yuan in safe, liquid principal-protected products using temporarily idle funds from a non-public stock issuance, aiming to enhance fund utilization efficiency and maximize shareholder benefits [2][3] Group 1 - The company will invest a maximum of 1.2 billion yuan in principal-protected products with a maximum term of 12 months [2] - The investment is intended to improve the efficiency of fund usage and increase company revenue [2] - The decision reflects the company's strategy to ensure maximum benefits for shareholders [2]